Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Current Neuropharmacology|May 5, 2023
Traditional and Innovative Anti-seizure Medications Targeting Key Physiopathological Mechanisms: Focus on Neurodevelopment and NeurodegenerationMiriam Sciaccaluga, Gabriele Ruffolo, Eleonora Palma, et al.
Pharmacological Research|September 24, 2016
Pharmacological modulation in mesial temporal lobe epilepsy: Current status and future perspectivesAntonio Gambardella, Angelo Labate, Pierangelo Cifelli, et al.
Current Pharmaceutical Design|August 12, 2017
Modulation of GABAA Receptors in the Treatment of EpilepsyEleonora Palma, Gabriele Ruffolo, Pierangelo Cifelli, et al.
Biomolecules|June 24, 2022
Classical and Unexpected Effects of Ultra-Micronized PEA in Neuromuscular FunctionPierangelo Cifelli, Gabriele Ruffolo, Marco Ceccanti, et al.
International Journal of Molecular Sciences|July 2, 2021
An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?Miriam Sciaccaluga, Alfredo Megaro, Giovanni Bellomo, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 21, 2022
Lipid mediator n-3 docosapentaenoic acid-derived protectin D1 enhances synaptic inhibition of hippocampal principal neurons by interaction with a G-protein-coupled receptorApostolos Mikroulis, Marco Ledri, Gabriele Ruffolo, et al.
Life (Basel, Switzerland)|December 23, 2022
GABAergic Neurotransmission in Human Tissues Is Modulated by CannabidiolGabriele Ruffolo, Alessandro Gaeta, Beatrice Cannata, et al.
International Journal of Molecular Sciences|January 26, 2020
Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission?Pierangelo Cifelli, Gabriele Ruffolo, Eleonora De Felice, et al.
Brain Sciences|April 3, 2021
Dissecting the Molecular Determinants of GABAA Receptors Current Rundown, a Hallmark of Refractory Human EpilepsyPierangelo Cifelli, Silvia Di Angelantonio, Veronica Alfano, et al.
Frontiers in Pharmacology|September 2, 2022
Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label studyMarco Ceccanti, Laura Libonati, Gabriele Ruffolo, et al.
Pageof 5